The estimated Net Worth of Laura J Schumacher is at least $117 Milión dollars as of 17 December 2021. Ms. Schumacher owns over 181,670 units of Abbvie Inc stock worth over $76,799,419 and over the last 20 years she sold ABBV stock worth over $25,048,201. In addition, she makes $15,142,800 as Vice Chairman a External Affairs and Chief Legal Officer at Abbvie Inc.
Sign up
Ms. Schumacher ABBV stock SEC Form 4 insiders trading
Laura has made over 49 trades of the Abbvie Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently she exercised 181,670 units of ABBV stock worth $10,380,624 on 17 December 2021.
The largest trade she's ever made was exercising 186,106 units of Abbvie Inc stock on 24 June 2016 worth over $5,140,248. On average, Laura trades about 9,933 units every 37 days since 2005. As of 17 December 2021 she still owns at least 394,673 units of Abbvie Inc stock.
You can see the complete history of Ms. Schumacher stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Laura Schumacher biography
Laura J. Schumacher is the Vice Chairman, External Affairs and Chief Legal Officer of the Company. Ms. Schumacher is AbbVie's Executive Vice President, External Affairs, General Counsel and Corporate Secretary, responsible for AbbVie's externally-facing functions of Health Economics Outcomes Research, Government Affairs, Corporate Responsibility, Brand and Communications. She also leads AbbVie's legal functions. Prior to AbbVie's separation from Abbott, Ms. Schumacher served as Executive Vice President, General Counsel and Corporate Secretary from 2007 to 2012, and as Senior Vice President, Corporate Secretary and General Counsel from 2005 to 2007. Both at Abbott and AbbVie, Ms. Schumacher also led Licensing and Acquisition and Ventures and Early Stage Collaborations. At Abbott, Ms. Schumacher was also responsible for its Office of Ethics and Compliance. Ms. Schumacher joined Abbott in 1990. She serves on the board of General Dynamics Corporation.
What is the salary of Laura Schumacher?
As the Vice Chairman a External Affairs and Chief Legal Officer of Abbvie Inc, the total compensation of Laura Schumacher at Abbvie Inc is $15,142,800. There are 1 executives at Abbvie Inc getting paid more, with Richard Gonzalez having the highest compensation of $21,610,600.
How old is Laura Schumacher?
Laura Schumacher is 56, she's been the Vice Chairman a External Affairs and Chief Legal Officer of Abbvie Inc since 2018. There are 16 older and 14 younger executives at Abbvie Inc. The oldest executive at Abbvie Inc is Edward Liddy, 73, who is the Independent Director.
What's Laura Schumacher's mailing address?
Laura's mailing address filed with the SEC is C/O GENERAL DYNAMICS CORPORATION, 11011 SUNSET HILLS ROAD, RESTON, VA, 20190.
Insiders trading at Abbvie Inc
Over the last 12 years, insiders at Abbvie Inc have traded over $324,915,370 worth of Abbvie Inc stock and bought 214,015 units worth $14,446,494 . The most active insiders traders include Richard A Gonzalez, Frederick H Waddell a Glenn F Tilton. On average, Abbvie Inc executives and independent directors trade stock every 22 days with the average trade being worth of $7,529,855. The most recent stock trade was executed by Richard A Gonzalez on 5 August 2024, trading 66,500 units of ABBV stock currently worth $12,403,580.
What does Abbvie Inc do?
AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.
What does Abbvie Inc's logo look like?
Complete history of Ms. Schumacher stock trades at Abbott Laboratories, Abbvie Inc, General Dynamics a Crowdstrike Inc
Abbvie Inc executives and stock owners
Abbvie Inc executives and other stock owners filed with the SEC include:
-
Richard Gonzalez,
Chairman of the Board, Chief Executive Officer -
Laura Schumacher,
Vice Chairman, External Affairs and Chief Legal Officer -
Carlos Alban,
Vice Chairman, Chief Commercial Officer -
Michael Severino,
President, Vice Chairman -
Robert Michael,
Chief Financial Officer, Senior Vice President -
William Chase,
Executive Vice President - Finance and Administration -
Richard A. Gonzalez,
Chairman & CEO -
Dr. Michael E. Severino,
Vice Chairman & Pres -
Laura J. Schumacher,
Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec. -
Timothy Richmond,
Chief Human Resource Officer, Executive Vice President -
Robert A. Michael,
Vice Chairman of Fin. & Commercial Operations and CFO -
Glenn Tilton,
Lead Independent Director -
Robert Alpern,
Independent Director -
Edward Rapp,
Independent Director -
Brett Hart,
Independent Director -
William Burnside,
Independent Director -
Roxanne Austin,
Independent Director -
Frederick Waddell,
Independent Director -
Melody Meyer,
Independent Director -
Edward Liddy,
Independent Director -
Thomas Freyman,
Independent Director -
Rebecca Roberts,
Independent Director -
Brian Durkin,
Vice President, Controller -
Jeffrey Stewart,
Senior Vice President, U.S. Commercial Operations -
Nicholas Donoghoe,
Senior Vice President - Enterprise Innovation -
Azita Saleki-Gerhardt,
Executive Vice President - Operations -
Henry Gosebruch,
Executive Vice President, Chief Strategy Officer -
Scott T. Reents,
Sr. VP & CFO -
Jeffrey Ryan Stewart,
Exec. VP & Chief Commercial Officer -
Henry O. Gosebruch,
Exec. VP & Chief Strategy Officer -
Scott C. Brun M.D.,
VP of Scientific Affairs & Head of AbbVie Ventures -
Timothy J. Richmond,
Exec. VP & Chief HR Officer -
Elizabeth Shea,
VP of Investor Relations -
Dr. Thomas J. Hudson,
Sr. VP of R&D and Chief Scientific Officer -
Dr. Azita Saleki-Gerhardt,
Exec. VP of Operations -
Thomas A. Hurwich,
VP, Controller -
Jennifer L. Davis,
-
Roy S Roberts,
Director -
Laboratories Abbott,
10% owner -
John M Leonard,
SVP, Chief Scientific Officer -
Elaine K. Sorg,
SVP, US COMMERCIAL OPERATIONS -
Perry C Siatis,
EVP, GC AND SECRETARY -
Carrie C Strom,
SVP & PRES GLOBAL ALLERG AESTH -
Thomas J Hudson,
SVP, CSO, GLOBAL RESEARCH -
Scott T Reents,
EVP, CHIEF FINANCIAL OFFICER -
Susan E Quaggin,
-
Kevin K Buckbee,
SVP, CONTROLLER -
Roopal Thakkar,
SVP, CMO, GLOBAL THERAPEUTICS